• Acute lymphoblastic leukemia (ALL) (in combination with other chemotherapy agents).

Contraindicated in:

• Hypersensitivity to pegylated L-asparinginase
• History of serious thrombosis during previous L-asparaginase therapy
• History of serious pancreatitis during previous L-asparaginase therapy
• History of serious hemorrhagic events during previous L-asparaginase therapy
• Severe hepatic impairment
• OB: Pregnancy (may cause fetal harm)
• Lactation: Lactation.

Use Cautiously in:

• Rep: Women of reproductive potential
• Pedi: Children <1 mo (safety and effectiveness not established).

CV: arrhythmias.

GI: pancreatitis, HEPATOTOXICITY, ↑bilirubin, ↑liver enzymes, diarrhea.

Hemat: thrombosis, HEMORRHAGE.

Resp: dyspnea.

Misc: hypersensitivity reactions (including anaphylaxis and angioedema), INFECTION.

Drug-Drug:

• May ↓ effectiveness of hormonal contraceptives.

• Solution for injection : 750 units/mL;

• IV (Adults and Children 1 mo-21 yr): 2500 units/m² every 21 days.

Asparlas

• Consists of l-asparaginase bound to monomethoxypolyethylene glycol (mPEG). This compound depletes asparagine (by converting it to aspartic acid and ammonia), which leukemic cells cannot synthesize. Normal cells are able to produce their own asparagine and are less susceptible to the effects of asparaginase. Binding to PEG renders asparaginase less antigenic and therefore less likely to induce hypersensitivity reactions.

• Death of leukemic cells.

Therapeutic Classification: antineoplastics

Pharmacologic Classification: enzymes

Absorption: IV administration results in complete bioavailability.

Distribution: Not distributed well to tissues.

Metabolism/Excretion: Unknown.

Half-life: 16.1 days.

(plasma concentrations)

• Explain purpose of medication to patient.
• Advise patient to notify health care professional immediately if signs and symptoms of hypersensitivity, pancreatitis, thromboembolism, hemorrhage, or hepatotoxicity (jaundice, severe nausea or vomiting, easy bruising or bleeding) occur.
• Advise patient to notify health care professional if excessive thirst or any increase in the volume or frequency of urination occurs.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
• Rep: May be teratogenic. Advise women of reproductive potential to use effective contraception, including a barrier method, and avoid breastfeeding during therapy and for at least 3 months after last dose. Notify health care professional if pregnancy is planned or suspected or if breastfeeding. Calasparagase can render hormonal contraceptives ineffective; use non-hormonal contraceptive methods.

kal-AS-par-jase

NDC Code^*

• 72694- Servier Pharmaceuticals LLC
  • 72694-515- asparlas
    • 72694-515-01- 1 VIAL, SINGLE-USE in 1 CARTON (72694-515-01) > 5 mL in 1 VIAL, SINGLE-USE